The recent successes of anti-tumor immunotherapy in multiple cancers highlight the central role of immunity in combating this disease. Although revolutionary, this therapeutic approach has not yet achieved the expected results for all patients. It is in this context that the “Therapeutic Innovations in Cancer Immunology” (TICI) team, led by Professor Olivier Adotevi and co-led by Professor Yann Godet, was established to address the scientific challenges raised by anti-tumor immunotherapy.
A better understanding of the interactions between T lymphocytes and tumors should enable us to select the right treatment for the right patient, improve the effectiveness of current immunotherapies, and develop new ones.
